ZOBIO EXTENDS NMR STRUCTURAL BIOLOGY COLLABORATION WITH SANOFI
29 January 2016, Leiden, NL
ZoBio announced today it will continue the collaboration with Sanofi in which ZoBio is providing critical 3D structure information to guide hit-to-lead studies. In the collaboration, ZoBio is using its expertise in nuclear magnetic resonance (NMR) of proteins and its unique access to high field NMR instrumentation to provide high resolution structures in a timely manner.
Despite having high resolution X-ray crystallographic structures of the protein, deriving structural information on target-inhibitor complexes has proven challenging. In some cases, it has not proven possible to “soak” the inhibitor into the crystals of the protein, while the other crystallographic structures have contained artifacts caused by e.g. protein – protein contacts within the crystal lattice. Using NMR, which observes the target – inhibitor complex in solution, ZoBio has been able to elucidate the physiologically relevant 3D structure of such complexes and provide details of the intermolecular interaction. The technique can also be used to search for appropriate chemical moieties to extend the inhibitor, thereby improving its potency and specificity.
”We are proud that Sanofi has selected ZoBio as a strategic partner for the development of new drugs.” said Gregg Siegal, CEO of ZoBio. “We are convinced that NMR is the ideal tool for structure based drug design where crystallography fails.”